No Data
No Data
Cytomed Therapeutics Announces First Patient Dosed in ANGELICA Trial
Express News | CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological...
Osteopore Teams Up With CytoMed Therapeutics for Cellular Product Development; Shares Up 3%
CytoMed Therapeutics Price Target Maintained With a $5.00/Share by Benchmark
CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
Earnings Preview: GDTC to Report Financial Results Pre-market on October 08